ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Sexually Transmitted Diseases (STD) Diagnostics Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: October 2025
|
Report Code: QYRE-Auto-5X17466
Home | Market Reports | Health| Reproductive Health
Global Sexually Transmitted Diseases STD Diagnostics Market Research Report 2024
BUY CHAPTERS

Global Sexually Transmitted Diseases (STD) Diagnostics Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-5X17466
Report
October 2025
Pages:117
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
F Hoffmann La Roche Ltd
Thermo Fisher Scientific Inc
Hologic Inc
Creative Diagnostics
Abbott Laboratories
Quest Diagnostics
BD
Qiagen NV
Cepheid Inc
Biomerieux

Sexually Transmitted Diseases (STD) Diagnostics Market

The global Sexually Transmitted Diseases (STD) Diagnostics market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
From a downstream perspective, Hospital accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Sexually Transmitted Diseases (STD) Diagnostics leading manufacturers including F.Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Hologic Inc., Creative Diagnostics, Abbott Laboratories, Quest Diagnostics, BD, QIAGEN, Cepheid, bioMerieux Inc., etc., dominate supply; the top five capture approximately % of global revenue, with F.Hoffmann-La Roche Ltd leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Sexually Transmitted Diseases (STD) Diagnostics market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of Sexually Transmitted Diseases (STD) Diagnostics Market Report

Report Metric Details
Report Name Sexually Transmitted Diseases (STD) Diagnostics Market
Segment by Type
Segment by Application
  • Hospital
  • Clinic
  • Others
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company F.Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Hologic Inc., Creative Diagnostics, Abbott Laboratories, Quest Diagnostics, BD, QIAGEN, Cepheid, bioMerieux Inc.
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the Sexually Transmitted Diseases (STD) Diagnostics study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
  • Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 14: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Sexually Transmitted Diseases (STD) Diagnostics Market report?

Ans: The main players in the Sexually Transmitted Diseases (STD) Diagnostics Market are F.Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Hologic Inc., Creative Diagnostics, Abbott Laboratories, Quest Diagnostics, BD, QIAGEN, Cepheid, bioMerieux Inc.

What are the Application segmentation covered in the Sexually Transmitted Diseases (STD) Diagnostics Market report?

Ans: The Applications covered in the Sexually Transmitted Diseases (STD) Diagnostics Market report are Hospital, Clinic, Others

What are the Type segmentation covered in the Sexually Transmitted Diseases (STD) Diagnostics Market report?

Ans: The Types covered in the Sexually Transmitted Diseases (STD) Diagnostics Market report are Molecular Test, Serologic Test, Point of Care Test, Others

Recommended Reports

Infectious Disease Diagnostics

STD & Related Diagnostics

Laboratory & Rapid Tests

1 Study Coverage
1.1 Introduction to Sexually Transmitted Diseases (STD) Diagnostics: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Sexually Transmitted Diseases (STD) Diagnostics Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Molecular Test
1.2.3 Serologic Test
1.2.4 Point of Care Test
1.2.5 Others
1.3 Market Segmentation by Application
1.3.1 Global Sexually Transmitted Diseases (STD) Diagnostics Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Sexually Transmitted Diseases (STD) Diagnostics Revenue Estimates and Forecasts 2020-2031
2.2 Global Sexually Transmitted Diseases (STD) Diagnostics Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Sexually Transmitted Diseases (STD) Diagnostics Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Sexually Transmitted Diseases (STD) Diagnostics Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Molecular Test Market Size by Players
3.3.2 Serologic Test Market Size by Players
3.3.3 Point of Care Test Market Size by Players
3.3.4 Others Market Size by Players
3.4 Global Sexually Transmitted Diseases (STD) Diagnostics Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Sexually Transmitted Diseases (STD) Diagnostics Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Sexually Transmitted Diseases (STD) Diagnostics Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Sexually Transmitted Diseases (STD) Diagnostics Market Size by Type (2020-2031)
6.4 North America Sexually Transmitted Diseases (STD) Diagnostics Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Sexually Transmitted Diseases (STD) Diagnostics Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Sexually Transmitted Diseases (STD) Diagnostics Market Size by Type (2020-2031)
7.4 Europe Sexually Transmitted Diseases (STD) Diagnostics Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Sexually Transmitted Diseases (STD) Diagnostics Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Sexually Transmitted Diseases (STD) Diagnostics Market Size by Type (2020-2031)
8.4 Asia-Pacific Sexually Transmitted Diseases (STD) Diagnostics Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Sexually Transmitted Diseases (STD) Diagnostics Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Sexually Transmitted Diseases (STD) Diagnostics Market Size by Type (2020-2031)
9.4 Central and South America Sexually Transmitted Diseases (STD) Diagnostics Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Sexually Transmitted Diseases (STD) Diagnostics Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Sexually Transmitted Diseases (STD) Diagnostics Market Size by Type (2020-2031)
10.4 Middle East and Africa Sexually Transmitted Diseases (STD) Diagnostics Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Sexually Transmitted Diseases (STD) Diagnostics Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 F.Hoffmann-La Roche Ltd
11.1.1 F.Hoffmann-La Roche Ltd Corporation Information
11.1.2 F.Hoffmann-La Roche Ltd Business Overview
11.1.3 F.Hoffmann-La Roche Ltd Sexually Transmitted Diseases (STD) Diagnostics Product Features and Attributes
11.1.4 F.Hoffmann-La Roche Ltd Sexually Transmitted Diseases (STD) Diagnostics Revenue and Gross Margin (2020-2025)
11.1.5 F.Hoffmann-La Roche Ltd Sexually Transmitted Diseases (STD) Diagnostics Revenue by Product in 2024
11.1.6 F.Hoffmann-La Roche Ltd Sexually Transmitted Diseases (STD) Diagnostics Revenue by Application in 2024
11.1.7 F.Hoffmann-La Roche Ltd Sexually Transmitted Diseases (STD) Diagnostics Revenue by Geographic Area in 2024
11.1.8 F.Hoffmann-La Roche Ltd Sexually Transmitted Diseases (STD) Diagnostics SWOT Analysis
11.1.9 F.Hoffmann-La Roche Ltd Recent Developments
11.2 Thermo Fisher Scientific Inc.
11.2.1 Thermo Fisher Scientific Inc. Corporation Information
11.2.2 Thermo Fisher Scientific Inc. Business Overview
11.2.3 Thermo Fisher Scientific Inc. Sexually Transmitted Diseases (STD) Diagnostics Product Features and Attributes
11.2.4 Thermo Fisher Scientific Inc. Sexually Transmitted Diseases (STD) Diagnostics Revenue and Gross Margin (2020-2025)
11.2.5 Thermo Fisher Scientific Inc. Sexually Transmitted Diseases (STD) Diagnostics Revenue by Product in 2024
11.2.6 Thermo Fisher Scientific Inc. Sexually Transmitted Diseases (STD) Diagnostics Revenue by Application in 2024
11.2.7 Thermo Fisher Scientific Inc. Sexually Transmitted Diseases (STD) Diagnostics Revenue by Geographic Area in 2024
11.2.8 Thermo Fisher Scientific Inc. Sexually Transmitted Diseases (STD) Diagnostics SWOT Analysis
11.2.9 Thermo Fisher Scientific Inc. Recent Developments
11.3 Hologic Inc.
11.3.1 Hologic Inc. Corporation Information
11.3.2 Hologic Inc. Business Overview
11.3.3 Hologic Inc. Sexually Transmitted Diseases (STD) Diagnostics Product Features and Attributes
11.3.4 Hologic Inc. Sexually Transmitted Diseases (STD) Diagnostics Revenue and Gross Margin (2020-2025)
11.3.5 Hologic Inc. Sexually Transmitted Diseases (STD) Diagnostics Revenue by Product in 2024
11.3.6 Hologic Inc. Sexually Transmitted Diseases (STD) Diagnostics Revenue by Application in 2024
11.3.7 Hologic Inc. Sexually Transmitted Diseases (STD) Diagnostics Revenue by Geographic Area in 2024
11.3.8 Hologic Inc. Sexually Transmitted Diseases (STD) Diagnostics SWOT Analysis
11.3.9 Hologic Inc. Recent Developments
11.4 Creative Diagnostics
11.4.1 Creative Diagnostics Corporation Information
11.4.2 Creative Diagnostics Business Overview
11.4.3 Creative Diagnostics Sexually Transmitted Diseases (STD) Diagnostics Product Features and Attributes
11.4.4 Creative Diagnostics Sexually Transmitted Diseases (STD) Diagnostics Revenue and Gross Margin (2020-2025)
11.4.5 Creative Diagnostics Sexually Transmitted Diseases (STD) Diagnostics Revenue by Product in 2024
11.4.6 Creative Diagnostics Sexually Transmitted Diseases (STD) Diagnostics Revenue by Application in 2024
11.4.7 Creative Diagnostics Sexually Transmitted Diseases (STD) Diagnostics Revenue by Geographic Area in 2024
11.4.8 Creative Diagnostics Sexually Transmitted Diseases (STD) Diagnostics SWOT Analysis
11.4.9 Creative Diagnostics Recent Developments
11.5 Abbott Laboratories
11.5.1 Abbott Laboratories Corporation Information
11.5.2 Abbott Laboratories Business Overview
11.5.3 Abbott Laboratories Sexually Transmitted Diseases (STD) Diagnostics Product Features and Attributes
11.5.4 Abbott Laboratories Sexually Transmitted Diseases (STD) Diagnostics Revenue and Gross Margin (2020-2025)
11.5.5 Abbott Laboratories Sexually Transmitted Diseases (STD) Diagnostics Revenue by Product in 2024
11.5.6 Abbott Laboratories Sexually Transmitted Diseases (STD) Diagnostics Revenue by Application in 2024
11.5.7 Abbott Laboratories Sexually Transmitted Diseases (STD) Diagnostics Revenue by Geographic Area in 2024
11.5.8 Abbott Laboratories Sexually Transmitted Diseases (STD) Diagnostics SWOT Analysis
11.5.9 Abbott Laboratories Recent Developments
11.6 Quest Diagnostics
11.6.1 Quest Diagnostics Corporation Information
11.6.2 Quest Diagnostics Business Overview
11.6.3 Quest Diagnostics Sexually Transmitted Diseases (STD) Diagnostics Product Features and Attributes
11.6.4 Quest Diagnostics Sexually Transmitted Diseases (STD) Diagnostics Revenue and Gross Margin (2020-2025)
11.6.5 Quest Diagnostics Recent Developments
11.7 BD
11.7.1 BD Corporation Information
11.7.2 BD Business Overview
11.7.3 BD Sexually Transmitted Diseases (STD) Diagnostics Product Features and Attributes
11.7.4 BD Sexually Transmitted Diseases (STD) Diagnostics Revenue and Gross Margin (2020-2025)
11.7.5 BD Recent Developments
11.8 QIAGEN
11.8.1 QIAGEN Corporation Information
11.8.2 QIAGEN Business Overview
11.8.3 QIAGEN Sexually Transmitted Diseases (STD) Diagnostics Product Features and Attributes
11.8.4 QIAGEN Sexually Transmitted Diseases (STD) Diagnostics Revenue and Gross Margin (2020-2025)
11.8.5 QIAGEN Recent Developments
11.9 Cepheid
11.9.1 Cepheid Corporation Information
11.9.2 Cepheid Business Overview
11.9.3 Cepheid Sexually Transmitted Diseases (STD) Diagnostics Product Features and Attributes
11.9.4 Cepheid Sexually Transmitted Diseases (STD) Diagnostics Revenue and Gross Margin (2020-2025)
11.9.5 Cepheid Recent Developments
11.10 bioMerieux Inc.
11.10.1 bioMerieux Inc. Corporation Information
11.10.2 bioMerieux Inc. Business Overview
11.10.3 bioMerieux Inc. Sexually Transmitted Diseases (STD) Diagnostics Product Features and Attributes
11.10.4 bioMerieux Inc. Sexually Transmitted Diseases (STD) Diagnostics Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
12 Sexually Transmitted Diseases (STD) DiagnosticsIndustry Chain Analysis
12.1 Sexually Transmitted Diseases (STD) Diagnostics Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Sexually Transmitted Diseases (STD) Diagnostics Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Sexually Transmitted Diseases (STD) Diagnostics Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
FEATURED COMPANIES
F Hoffmann La Roche Ltd
Thermo Fisher Scientific Inc
Hologic Inc
Creative Diagnostics
Abbott Laboratories
Quest Diagnostics
BD
Qiagen NV
Cepheid Inc
Biomerieux
List of Tables
 Table 1. Global Sexually Transmitted Diseases (STD) Diagnostics Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global Sexually Transmitted Diseases (STD) Diagnostics Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global Sexually Transmitted Diseases (STD) Diagnostics Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global Sexually Transmitted Diseases (STD) Diagnostics Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Sexually Transmitted Diseases (STD) Diagnostics Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 7. Global Sexually Transmitted Diseases (STD) Diagnostics Revenue by Players (2020-2025) & (US$ Million)
 Table 8. Global Sexually Transmitted Diseases (STD) Diagnostics Revenue Market Share by Players (2020-2025)
 Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 10. Global Sexually Transmitted Diseases (STD) Diagnostics by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Sexually Transmitted Diseases (STD) Diagnostics as of 2024)
 Table 11. Global Sexually Transmitted Diseases (STD) Diagnostics Average Gross Margin (%) by Player (2020 VS 2024)
 Table 12. Global Sexually Transmitted Diseases (STD) Diagnostics Companies Headquarters
 Table 13. Global Sexually Transmitted Diseases (STD) Diagnostics Market Concentration Ratio (CR5 and HHI)
 Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 16. Global Sexually Transmitted Diseases (STD) Diagnostics Revenue by Type (2020-2025) & (US$ Million)
 Table 17. Global Sexually Transmitted Diseases (STD) Diagnostics Revenue by Type (2026-2031) & (US$ Million)
 Table 18. Key Product Attributes and Differentiation
 Table 19. Global Sexually Transmitted Diseases (STD) Diagnostics Revenue by Application (2020-2025) & (US$ Million)
 Table 20. Global Sexually Transmitted Diseases (STD) Diagnostics Revenue by Application (2026-2031) & (US$ Million)
 Table 21. Sexually Transmitted Diseases (STD) Diagnostics High-Growth Sectors Demand CAGR (2024-2031)
 Table 22. Top Customers by Region
 Table 23. Top Customers by Application
 Table 24. North America Sexually Transmitted Diseases (STD) Diagnostics Growth Accelerators and Market Barriers
 Table 25. North America Sexually Transmitted Diseases (STD) Diagnostics Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 26. Europe Sexually Transmitted Diseases (STD) Diagnostics Growth Accelerators and Market Barriers
 Table 27. Europe Sexually Transmitted Diseases (STD) Diagnostics Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 28. Asia-Pacific Sexually Transmitted Diseases (STD) Diagnostics Growth Accelerators and Market Barriers
 Table 29. Asia-Pacific Sexually Transmitted Diseases (STD) Diagnostics Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 30. Central and South America Sexually Transmitted Diseases (STD) Diagnostics Investment Opportunities and Key Challenges
 Table 31. Central and South America Sexually Transmitted Diseases (STD) Diagnostics Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 32. Middle East and Africa Sexually Transmitted Diseases (STD) Diagnostics Investment Opportunities and Key Challenges
 Table 33. Middle East and Africa Sexually Transmitted Diseases (STD) Diagnostics Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 34. F.Hoffmann-La Roche Ltd Corporation Information
 Table 35. F.Hoffmann-La Roche Ltd Description and Major Businesses
 Table 36. F.Hoffmann-La Roche Ltd Product Features and Attributes
 Table 37. F.Hoffmann-La Roche Ltd Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 38. F.Hoffmann-La Roche Ltd Revenue Proportion by Product in 2024
 Table 39. F.Hoffmann-La Roche Ltd Revenue Proportion by Application in 2024
 Table 40. F.Hoffmann-La Roche Ltd Revenue Proportion by Geographic Area in 2024
 Table 41. F.Hoffmann-La Roche Ltd Sexually Transmitted Diseases (STD) Diagnostics SWOT Analysis
 Table 42. F.Hoffmann-La Roche Ltd Recent Developments
 Table 43. Thermo Fisher Scientific Inc. Corporation Information
 Table 44. Thermo Fisher Scientific Inc. Description and Major Businesses
 Table 45. Thermo Fisher Scientific Inc. Product Features and Attributes
 Table 46. Thermo Fisher Scientific Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 47. Thermo Fisher Scientific Inc. Revenue Proportion by Product in 2024
 Table 48. Thermo Fisher Scientific Inc. Revenue Proportion by Application in 2024
 Table 49. Thermo Fisher Scientific Inc. Revenue Proportion by Geographic Area in 2024
 Table 50. Thermo Fisher Scientific Inc. Sexually Transmitted Diseases (STD) Diagnostics SWOT Analysis
 Table 51. Thermo Fisher Scientific Inc. Recent Developments
 Table 52. Hologic Inc. Corporation Information
 Table 53. Hologic Inc. Description and Major Businesses
 Table 54. Hologic Inc. Product Features and Attributes
 Table 55. Hologic Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 56. Hologic Inc. Revenue Proportion by Product in 2024
 Table 57. Hologic Inc. Revenue Proportion by Application in 2024
 Table 58. Hologic Inc. Revenue Proportion by Geographic Area in 2024
 Table 59. Hologic Inc. Sexually Transmitted Diseases (STD) Diagnostics SWOT Analysis
 Table 60. Hologic Inc. Recent Developments
 Table 61. Creative Diagnostics Corporation Information
 Table 62. Creative Diagnostics Description and Major Businesses
 Table 63. Creative Diagnostics Product Features and Attributes
 Table 64. Creative Diagnostics Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 65. Creative Diagnostics Revenue Proportion by Product in 2024
 Table 66. Creative Diagnostics Revenue Proportion by Application in 2024
 Table 67. Creative Diagnostics Revenue Proportion by Geographic Area in 2024
 Table 68. Creative Diagnostics Sexually Transmitted Diseases (STD) Diagnostics SWOT Analysis
 Table 69. Creative Diagnostics Recent Developments
 Table 70. Abbott Laboratories Corporation Information
 Table 71. Abbott Laboratories Description and Major Businesses
 Table 72. Abbott Laboratories Product Features and Attributes
 Table 73. Abbott Laboratories Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 74. Abbott Laboratories Revenue Proportion by Product in 2024
 Table 75. Abbott Laboratories Revenue Proportion by Application in 2024
 Table 76. Abbott Laboratories Revenue Proportion by Geographic Area in 2024
 Table 77. Abbott Laboratories Sexually Transmitted Diseases (STD) Diagnostics SWOT Analysis
 Table 78. Abbott Laboratories Recent Developments
 Table 79. Quest Diagnostics Corporation Information
 Table 80. Quest Diagnostics Description and Major Businesses
 Table 81. Quest Diagnostics Product Features and Attributes
 Table 82. Quest Diagnostics Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 83. Quest Diagnostics Recent Developments
 Table 84. BD Corporation Information
 Table 85. BD Description and Major Businesses
 Table 86. BD Product Features and Attributes
 Table 87. BD Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 88. BD Recent Developments
 Table 89. QIAGEN Corporation Information
 Table 90. QIAGEN Description and Major Businesses
 Table 91. QIAGEN Product Features and Attributes
 Table 92. QIAGEN Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 93. QIAGEN Recent Developments
 Table 94. Cepheid Corporation Information
 Table 95. Cepheid Description and Major Businesses
 Table 96. Cepheid Product Features and Attributes
 Table 97. Cepheid Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 98. Cepheid Recent Developments
 Table 99. bioMerieux Inc. Corporation Information
 Table 100. bioMerieux Inc. Description and Major Businesses
 Table 101. bioMerieux Inc. Product Features and Attributes
 Table 102. bioMerieux Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 103. bioMerieux Inc. Recent Developments
 Table 104. Raw Materials Key Suppliers
 Table 105. Distributors List
 Table 106. Market Trends and Market Evolution
 Table 107. Market Drivers and Opportunities
 Table 108. Market Challenges, Risks, and Restraints
 Table 109. Research Programs/Design for This Report
 Table 110. Key Data Information from Secondary Sources
 Table 111. Key Data Information from Primary Sources


List of Figures
 Figure 1. Sexually Transmitted Diseases (STD) Diagnostics Product Picture
 Figure 2. Global Sexually Transmitted Diseases (STD) Diagnostics Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. Molecular Test Product Picture
 Figure 4. Serologic Test Product Picture
 Figure 5. Point of Care Test Product Picture
 Figure 6. Others Product Picture
 Figure 7. Global Sexually Transmitted Diseases (STD) Diagnostics Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 8. Hospital
 Figure 9. Clinic
 Figure 10. Others
 Figure 11. Sexually Transmitted Diseases (STD) Diagnostics Report Years Considered
 Figure 12. Global Sexually Transmitted Diseases (STD) Diagnostics Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 13. Global Sexually Transmitted Diseases (STD) Diagnostics Revenue (2020-2031) & (US$ Million)
 Figure 14. Global Sexually Transmitted Diseases (STD) Diagnostics Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 15. Global Sexually Transmitted Diseases (STD) Diagnostics Revenue Market Share by Region (2020-2031)
 Figure 16. Global Sexually Transmitted Diseases (STD) Diagnostics Revenue Market Share Ranking (2024)
 Figure 17. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 18. Molecular Test Revenue Market Share by Player in 2024
 Figure 19. Serologic Test Revenue Market Share by Player in 2024
 Figure 20. Point of Care Test Revenue Market Share by Player in 2024
 Figure 21. Others Revenue Market Share by Player in 2024
 Figure 22. Global Sexually Transmitted Diseases (STD) Diagnostics Revenue Market Share by Type (2020-2031)
 Figure 23. Global Sexually Transmitted Diseases (STD) Diagnostics Revenue Market Share by Application (2020-2031)
 Figure 24. North America Sexually Transmitted Diseases (STD) Diagnostics Revenue YoY (2020-2031) & (US$ Million)
 Figure 25. North America Top 5 Players Sexually Transmitted Diseases (STD) Diagnostics Revenue (US$ Million) in 2024
 Figure 26. North America Sexually Transmitted Diseases (STD) Diagnostics Revenue (US$ Million) by Type (2020 - 2031)
 Figure 27. North America Sexually Transmitted Diseases (STD) Diagnostics Revenue (US$ Million) by Application (2020-2031)
 Figure 28. US Sexually Transmitted Diseases (STD) Diagnostics Revenue (2020-2031) & (US$ Million)
 Figure 29. Canada Sexually Transmitted Diseases (STD) Diagnostics Revenue (2020-2031) & (US$ Million)
 Figure 30. Mexico Sexually Transmitted Diseases (STD) Diagnostics Revenue (2020-2031) & (US$ Million)
 Figure 31. Europe Sexually Transmitted Diseases (STD) Diagnostics Revenue YoY (2020-2031) & (US$ Million)
 Figure 32. Europe Top 5 Players Sexually Transmitted Diseases (STD) Diagnostics Revenue (US$ Million) in 2024
 Figure 33. Europe Sexually Transmitted Diseases (STD) Diagnostics Revenue (US$ Million) by Type (2020-2031)
 Figure 34. Europe Sexually Transmitted Diseases (STD) Diagnostics Revenue (US$ Million) by Application (2020-2031)
 Figure 35. Germany Sexually Transmitted Diseases (STD) Diagnostics Revenue (2020-2031) & (US$ Million)
 Figure 36. France Sexually Transmitted Diseases (STD) Diagnostics Revenue (2020-2031) & (US$ Million)
 Figure 37. U.K. Sexually Transmitted Diseases (STD) Diagnostics Revenue (2020-2031) & (US$ Million)
 Figure 38. Italy Sexually Transmitted Diseases (STD) Diagnostics Revenue (2020-2031) & (US$ Million)
 Figure 39. Russia Sexually Transmitted Diseases (STD) Diagnostics Revenue (2020-2031) & (US$ Million)
 Figure 40. Asia-Pacific Sexually Transmitted Diseases (STD) Diagnostics Revenue YoY (2020-2031) & (US$ Million)
 Figure 41. Asia-Pacific Top 8 Players Sexually Transmitted Diseases (STD) Diagnostics Revenue (US$ Million) in 2024
 Figure 42. Asia-Pacific Sexually Transmitted Diseases (STD) Diagnostics Revenue (US$ Million) by Type (2020-2031)
 Figure 43. Asia-Pacific Sexually Transmitted Diseases (STD) Diagnostics Revenue (US$ Million) by Application (2020-2031)
 Figure 44. Indonesia Sexually Transmitted Diseases (STD) Diagnostics Revenue (2020-2031) & (US$ Million)
 Figure 45. Japan Sexually Transmitted Diseases (STD) Diagnostics Revenue (2020-2031) & (US$ Million)
 Figure 46. South Korea Sexually Transmitted Diseases (STD) Diagnostics Revenue (2020-2031) & (US$ Million)
 Figure 47. Australia Sexually Transmitted Diseases (STD) Diagnostics Revenue (2020-2031) & (US$ Million)
 Figure 48. India Sexually Transmitted Diseases (STD) Diagnostics Revenue (2020-2031) & (US$ Million)
 Figure 49. Indonesia Sexually Transmitted Diseases (STD) Diagnostics Revenue (2020-2031) & (US$ Million)
 Figure 50. Vietnam Sexually Transmitted Diseases (STD) Diagnostics Revenue (2020-2031) & (US$ Million)
 Figure 51. Malaysia Sexually Transmitted Diseases (STD) Diagnostics Revenue (2020-2031) & (US$ Million)
 Figure 52. Philippines Sexually Transmitted Diseases (STD) Diagnostics Revenue (2020-2031) & (US$ Million)
 Figure 53. Singapore Sexually Transmitted Diseases (STD) Diagnostics Revenue (2020-2031) & (US$ Million)
 Figure 54. Central and South America Sexually Transmitted Diseases (STD) Diagnostics Revenue YoY (2020-2031) & (US$ Million)
 Figure 55. Central and South America Top 5 Players Sexually Transmitted Diseases (STD) Diagnostics Revenue (US$ Million) in 2024
 Figure 56. Central and South America Sexually Transmitted Diseases (STD) Diagnostics Revenue (US$ Million) by Type (2020-2031)
 Figure 57. Central and South America Sexually Transmitted Diseases (STD) Diagnostics Revenue (US$ Million) by Application (2020-2031)
 Figure 58. Brazil Sexually Transmitted Diseases (STD) Diagnostics Revenue (2020-2025) & (US$ Million)
 Figure 59. Argentina Sexually Transmitted Diseases (STD) Diagnostics Revenue (2020-2025) & (US$ Million)
 Figure 60. Middle East and Africa Sexually Transmitted Diseases (STD) Diagnostics Revenue YoY (2020-2031) & (US$ Million)
 Figure 61. Middle East and Africa Top 5 Players Sexually Transmitted Diseases (STD) Diagnostics Revenue (US$ Million) in 2024
 Figure 62. South America Sexually Transmitted Diseases (STD) Diagnostics Revenue (US$ Million) by Type (2020-2031)
 Figure 63. Middle East and Africa Sexually Transmitted Diseases (STD) Diagnostics Revenue (US$ Million) by Application (2020-2031)
 Figure 64. GCC Countries Sexually Transmitted Diseases (STD) Diagnostics Revenue (2020-2025) & (US$ Million)
 Figure 65. Israel Sexually Transmitted Diseases (STD) Diagnostics Revenue (2020-2025) & (US$ Million)
 Figure 66. Egypt Sexually Transmitted Diseases (STD) Diagnostics Revenue (2020-2025) & (US$ Million)
 Figure 67. South Africa Sexually Transmitted Diseases (STD) Diagnostics Revenue (2020-2025) & (US$ Million)
 Figure 68. Sexually Transmitted Diseases (STD) Diagnostics Industry Chain Mapping
 Figure 69. Channels of Distribution (Direct Vs Distribution)
 Figure 70. Bottom-up and Top-down Approaches for This Report
 Figure 71. Data Triangulation
 Figure 72. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Nano Dimension

SIMILAR REPORTS

Global Sexually Transmitted Diseases STD Treatment Market Research Report 2024
Global Sexually Transmitted Diseases STDs Testing Devices Market Research Report 2025
Global STD Tests Market Research Report 2024
Global Sexually Transmitted Diseases Test Kit Market Research Report 2025
Global Chlamydia Infection Diagnostics Market Research Report 2024
Global Diagnostic Testing For STDs Market Insights Forecast to 2030
Global Home Sexually Transmitted Diseases Test Kit Market Research Report 2025
Global Sexually Transmitted Diseases STD Testing Market Insights Forecast to 2030
Chlamydia Diagnostic Testing Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Syphilis Diagnosis Market Research Report 2024
Global STD Testing Kits Market Research Report 2024
Global Sexually Transmitted Disease STD Testing Market Insights Forecast to 2030
Global Sexually Transmitted Diseases Drug Market Research Report 2025
STD Diagnostics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Infectious Diseases Molecular Diagnostics Market Research Report 2025
STD Home Test Kits Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Infectious Disease Testing And Diagnostic Market Research Report 2024
Global Chlamydia Trachomatis Detection Kit Market Research Report 2024
STDs Diagnosis Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Chlamydia Infection Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions